Human Immune Globulin Intravenous Market was valued at USD 12.8 Billion in 2022 and is projected to reach USD 21.5 Billion by 2030, growing at a CAGR of 7.5% from 2024 to 2030.
The global Human Immune Globulin Intravenous IVIG market is currently experiencing substantial growth driven by increasing demand for immunoglobulin therapies across various therapeutic areas. Human Immune Globulin Intravenous is a blood derived product used for treating a variety of autoimmune diseases primary immunodeficiencies and neurological conditions. As of 2023 the global IVIG market is valued at approximately USD 13 billion and is projected to grow at a compound annual growth rate CAGR of 8% from 2023 to 2030 with an expected market value of around USD 22 billion by 2030.
Key drivers for the market’s growth include a rise in autoimmune diseases increasing prevalence of primary immunodeficiencies and advancements in treatment options. Additionally growing awareness among healthcare professionals and patients about the benefits of IVIG therapy along with improved healthcare infrastructure especially in emerging economies has significantly contributed to the market's growth. The market is also witnessing innovations such as the development of subcutaneous immunoglobulin therapies and the use of advanced technology in production processes which further supports its expansion.
Get an In-Depth Research Analysis of the Global Human Immune Globulin Intravenous Market Size And Forecast [2025-2032]
Rising Incidence of Autoimmune Disorders: Autoimmune diseases such as rheumatoid arthritis lupus and multiple sclerosis are becoming increasingly prevalent driving demand for immunoglobulin therapies.
Prevalence of Primary Immunodeficiencies: Disorders like Common Variable Immunodeficiency CVID and X linked agammaglobulinemia lead to higher consumption of IVIG products particularly in pediatric populations.
Technological Advancements in IVIG Production: The evolution of manufacturing processes including the use of nanofiltration and high efficiency purification methods has enhanced the safety and quality of IVIG products fostering market growth.
High Cost of Treatment: The high cost associated with IVIG therapy can be a barrier for patients especially in low income regions. The need for substantial healthcare reimbursements also poses challenges for widespread accessibility.
Supply Chain Issues: Limited blood donor availability and challenges in the collection and processing of plasma can restrict supply affecting market growth.
Growth in Emerging Markets: There is significant growth potential in regions like Asia Pacific Latin America and the Middle East where healthcare infrastructure improvements and rising healthcare awareness drive IVIG demand.
Shift Towards Subcutaneous Immunoglobulin Therapy: Subcutaneous forms of IVIG have gained traction due to their convenience and reduced side effects creating opportunities for innovation in drug delivery systems.
Regulatory Support and Initiatives: Governments and health organizations globally are increasingly recognizing the importance of immunoglobulin therapies providing regulatory support for market growth.
Innovations in biotechnology such as gene therapies and biosimilars for IVIG are expected to revolutionize treatment options improving both efficacy and affordability. Additionally advancements in recombinant DNA technology and the production of recombinant immunoglobulin therapies will further enhance the clinical outcomes of IVIG based treatments.
As the market grows there is an increasing focus on sustainable plasma sourcing. Ethical plasma collection practices and advancements in plasma fractionation are being explored to ensure that supply meets the rising demand without compromising sustainability.
Immunodeficiency Diseases: Disorders like CVID and severe combined immunodeficiency SCID require long term IVIG therapy contributing significantly to market growth.
Autoimmune Disorders: Diseases such as rheumatoid arthritis lupus and Guillain Barré syndrome use IVIG for immune modulation further expanding the market's application base.
Neurological Disorders: Conditions like chronic inflammatory demyelinating polyneuropathy CIDP and multifocal motor neuropathy MMN are increasingly treated with IVIG boosting demand in this segment.
Hospitals and Clinics: The hospital segment is the largest end user owing to the high demand for IVIG treatments in specialized healthcare settings.
Homecare Settings: The growing trend of home based IVIG therapy enabled by subcutaneous immunoglobulin formulations is gaining traction among patients especially in developed regions.
North America: The largest market for IVIG driven by high healthcare spending well established healthcare infrastructure and an aging population.
Europe: Second in market share with strong growth driven by increasing demand for IVIG in autoimmune and neurological disorders.
Asia Pacific: The fastest growing region fueled by improving healthcare systems rising awareness of immunodeficiencies and economic growth in countries like India and China.
The IVIG market is highly competitive with several key players dominating the global landscape:
Grifols S.A.: A leading company in the IVIG market Grifols offers a range of immunoglobulin products and has significant market presence globally.
CSL Behring: Known for its strong product portfolio and presence in both developed and emerging markets CSL Behring is a key contributor to the growth of IVIG therapies.
Octapharma AG: With a focus on plasma derived therapies Octapharma has been a major player in the global IVIG market.
Shire Pharmaceuticals now part of Takeda: A key player with a comprehensive portfolio of immunoglobulin products Shire’s acquisition by Takeda has strengthened its position in the market.
Several key trends and innovations are shaping the future of the IVIG market:
Subcutaneous Immunoglobulin SCIG: The development of SCIG products is a major trend as these therapies offer patients a more convenient and less invasive alternative to traditional intravenous administration.
Biosimilars: The increasing availability of biosimilar IVIG products has created opportunities for market expansion providing more affordable options for patients.
Genetic Research and Personalized Medicine: Ongoing research into gene therapies and the genetic underpinnings of immune disorders is expected to lead to more targeted and effective IVIG treatments.
Supply Chain Challenges: Limited plasma donation availability and complexities in processing plasma can create supply chain bottlenecks.
High Costs of Treatment: IVIG is a costly treatment and many healthcare systems struggle with reimbursement for long term therapies.
Regulatory Hurdles: Strict regulations around plasma collection and IVIG production can slow down market growth in certain regions.
Plasma Collection Innovation: Investment in advanced plasma collection technologies and increased donor recruitment can address supply challenges.
Cost Reduction Strategies: The introduction of biosimilars and improvements in production efficiency can help reduce treatment costs.
Regulatory Streamlining: Efforts to streamline regulatory frameworks and standardize quality control measures can ease market access.
The Human Immune Globulin Intravenous market is poised for significant growth in the coming years. Continued advances in biotechnology a rising global incidence of autoimmune and immunodeficiency diseases and increasing healthcare access in emerging markets will drive demand. The shift toward more patient friendly treatment options such as subcutaneous immunoglobulin along with the adoption of biosimilars will also contribute to market growth. However challenges related to cost supply chain and regulatory barriers must be addressed to ensure sustainable expansion.
What are the leading regions in the IVIG market?
North America and Europe dominate the market but Asia Pacific is expected to grow at the highest rate due to improving healthcare infrastructure and rising awareness.
What are the primary applications of IVIG?
IVIG is used to treat autoimmune diseases primary immunodeficiencies and neurological conditions such as CIDP.
What are the challenges facing the IVIG market?
Challenges include high costs supply chain limitations and regulatory hurdles all of which impact market accessibility and affordability.
Who are the major players in the IVIG market?
Key players include Grifols CSL Behring Octapharma AG and Takeda Shire Pharmaceuticals.
What is the future growth potential of the IVIG market?
The market is expected to grow significantly due to technological advancements rising disease prevalence and increased demand for immunoglobulin therapies.
```
Takeda
Grifols
CSL
Octapharma
Biotest
Kedrion
Hualan Bio
CNBG
Shanghai RAAS
CBPO
Takeda
BPL
Sichuan Yuanda Shuyang
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Human Immune Globulin Intravenous Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Human Immune Globulin Intravenous Market
Immunodeficiency
Autoimmune Disease
Acute Infection
Based on Types the Market is categorized into Below types that held the largest Human Immune Globulin Intravenous market share In 2023.
IVIg Liquid
IVIg Powder
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Human Immune Globulin Intravenous Market Research Analysis
1. Introduction of the Global Human Immune Globulin Intravenous Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Human Immune Globulin Intravenous Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Human Immune Globulin Intravenous Market, By Type
6. Global Human Immune Globulin Intravenous Market, By Application
7. Global Human Immune Globulin Intravenous Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Human Immune Globulin Intravenous Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/